Floatz logo

DICLOFENAC

Benign Prostatic Hyperplasia

Taha UçarSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Benign Prostatic Hyperplasia cohort.

Asset / SponsorPhaseRating
Dinitrogen Monoxide
Beth Israel Deaconess Medical Center
Phase 4BB
AVOLVE
Turku University Hospital
Phase 4BB
Testosterone Undecylate
University of Florence
Phase 4BB
Oxygen
Beth Israel Deaconess Medical Center
Phase 4BB
DOXAZOSIN
Buddhist Tzu Chi General Hospital
Phase 2B

View all 17 →

Same molecule, other indications

DICLOFENAC is also rated in:

arthropathyDormant
BBB
Indicative · Phase 4
73 / 100
View asset →
chronic pain syndromeActive
BB
Indicative · Phase 4
66 / 100
View asset →
subarachnoid hemorrhageDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →